TABLE 1.
Diagnostic performance of the novel peptide mixtures and of ESAT-6 and CFP-10 alone and in combination for the derivation panel
| Antigen(s) | Recognitiona (no. responding/no. tested) | Sensitivity,b % (95% CI) | Specificity,c %(95% CI) |
|---|---|---|---|
| Rv2654 | 28/59 | 47 (35-60) | 97 (90-103) |
| Rv3873A | 27/59 | 46 (33-57) | 97 (90-103) |
| Rv3878B | 14/44 | 32 (18-46) | 97 (90-103) |
| Rv2654 + Rv3873A + Rv3878B | 25/44 | 57 (42-72) | 97 (90-103) |
| ESAT-6 | 44/59 | 75 (64-86) | 97 (90-103) |
| CFP-10 | 39/59 | 66 (54-78) | 97 (90-103) |
| ESAT-6 + CFP-10 | 48/59 | 81 (71-91) | 97 (90-103) |
| ESAT-6 + CFP-10 + Rv2654 + Rv3873A + Rv3878B | 37/44 | 84 (73-95) | 97 (90-103) |
a
Number of patients responding/number tested. The cutoff was determined by receiver-operating characteristic curve analysis; there was ≥97% specificity for the single proteins and peptide cocktails: ESAT-6, 94 pg/ml; CFP-10, 80 pg/ml; Rv2654, 53 pg/ml; Rv3873A, 73 pg/ml; and Rv3878B, 38 pg/ml.
b
Percentage of responding patients out of all patients tested.
c
Percentage of true-negative controls out of all control individuals tested.